Neuronetics, Inc. is a privately held medical device company focused on commercializing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Neuronetics is the leader in the development of TMS Therapy® (transcranial magnetic stimulation), a non-invasive form of neuromodulation. In October 2008, Neuronetics received FDA clearance to market its NeuroStar TMS Therapy® system for patients suffering from major depression and who have failed to benefit from initial antidepressant medication. The Company is currently marketing the NeuroStar® system in the U.S. via a direct sales force.
Using Transcranial Magnetic Stimulation (TMS), Neuronetics develops safe therapies for disorders of the central nervous system, including major depression, schizophrenia, OCD, mania and epilepsy.
The company has completed A, B, C, D and E rounds of funding, raising a total of $128 million.
31 General Warren Blvd.
Malvern, PA 19355-1245
» Read how Neuronetics Brightens Outlook For Neuro Devices
For more information on the NeuroStar TMS Therapy, please fo to www.neurostar.com